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2108Objective: The perioperative outcomes of the endovascular approach to aortobronchial fistula have been
favorable. However, it is uncertain whether thoracic endovascular aneurysm repair (TEVAR) alone provides
a complete and durable cure for an aortobronchial fistula. TEVAR does nothing to address the issue of the defect
in the respiratory tract, leaving the patient at risk of aortobronchial fistula recurrence and/or stent graft infection.
The authors believe that the bronchial defect should be addressed.
Methods: Over the last 10 years, 5 patients were treated for an aortobronchial fistula using a combined
endovascular and surgical approach (primary treatment in 3 patients and secondary after TEVAR in 2 patients).
All the patients underwent emergency stent graft placement and concomitant (n ¼ 1) or staged (n ¼ 4) open
repair including pulmonary resection with coverage of the stent graft using muscle or pleural flaps. All patients
received a 6-week course of broad-spectrum intravenous antibiotics followed by lifelong oral antibiotics.
Results: All patients survived the surgical procedure. After a mean follow-up of 23.2 months, 4 patients are
asymptomatic and postprocedure computed tomography scans were unremarkable. One patient treated for an
aortobronchial fistula after TEVAR was readmitted 4 months after surgical conversion. Stent graft explantation
and silver-coated tube graft replacement of the descending thoracic aorta were performed for severe
mediastinitis with associated thoracic stent graft infection. The postoperative course of this patient was
uneventful.
Conclusions: Emergency TEVAR for an aortobronchial fistula is an appealing strategy for this devastating
complication. However, to achieve a lasting result, direct contact between the stent graft and the pulmonary
tissue should be avoided to prevent further erosive damage. Concomitant or staged repair should entail primary
repair or resection and anastomosis of the bronchus and/or pulmonary resection with coverage of the stent graft
using muscle or pleural flaps combined with broad-spectrum intravenous antibiotic therapy. Long-term
surveillance and continued investigation are warranted. (J Thorac Cardiovasc Surg 2014;148:2108-11)Aortobronchial fistula is a rare clinical entity. A literature
review published in 2013 identified only 124 patients.1
Untreated primary and secondary aortobronchial fistulae
are fatal and remain a formidable surgical problem in older
high-risk patients with hemorrhagic shock or sepsis.
Despite significant improvement in surgical techniques,
the operative mortality of open aortobronchial fistula repair
ranges from 15% to 41%.2 The high mortality is related to
the need for thoracotomy, thoracic aortic crossclamping,
and the surgical replacement or repair of the thoracic aorta
with concomitant resection of the pulmonary segments
involved. Moreover, redo operations, performed for
secondary fistulas, are associated with increased bleedinge Department of Thoracic and Vascular Surgery, Arnaud de Villeneuve
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morbidity and mortality.
Within the last decade, several case reports have
described initial success with treatment of aortobronchial
fistulas using thoracic stent grafts, suggesting more wide-
spread use of this approach. The perioperative outcomes
of the endovascular approach have been favorable with
low 30-day mortality (6.4%) and no cases of paraplegia.1
Concerns remain, however, about the risk of aortobronchial
fistula recurrence and/or infection of the stent graft with the
endovascular approach.2 We have recently performed a
systematic review of the literature1 and reported that
recurrence of the aortobronchial fistula and stent graft
infection were observed in 11.2% and 1.7% of patients,
respectively. Surgical conversion was required in 4.3% of
patients. To decrease the risk of recurrence, we believe
that the bronchial defect should be addressed. Direct con-
tact between the stent graft and pulmonary tissues should
be avoided to prevent further erosive damage. The concom-
itant repair may entail primary repair or resection and anas-
tomosis of the bronchus and/or pulmonary resection with
coverage of the stent graft using muscle or pleural flaps.gery c November 2014
Abbreviations and Acronyms
CT ¼ computed tomography
TEVAR ¼ thoracic endovascular aneurysm repair
Canaud et al Acquired Cardiovascular DiseaseThe aim of this article was to present our experience
of the combined endovascular and surgical approach for
aortobronchial fistula.A
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DMETHODS
Patients treated for an aortobronchial fistula in our department
between 2003 and 2013 were reviewed. Five patients were included.
The clinical features, treatment modalities, and outcomes are summarized
in Tables 1 and 2.
Primary Aortobronchial Fistula
Two women (aged 75 and 84 years) and 1 man (89 year old) underwent
emergency thoracic endovascular aneurysm repair (TEVAR) for primary
aortobronchial fistula. The 84-year-old woman had miliary tuberculosis.
Two different stent grafts were used: Conformable-TAG (n ¼ 2) (WL
Gore & Associates, Inc, Flagstaff, Ariz) and Valiant stent graft (n ¼ 1)
(Medtronic Inc, Minneapolis, Minn). A concomitant left upper lobectomy
was performed in 1 patient, and a left lower lobectomy or a pulmonary
segmentectomy was performed as a staged procedure in the other 2
patients. For all patients, aortic debridement and coverage of the stent
graft was achieved using pleural or pericardial flaps (Figure 1). Radical
aortic debridement included resection of the necrotic tissues until the
stent graft was visible. Two patients received a 6-week course of
broad-spectrum intravenous antibiotics followed by lifelong oral
antibiotic suppression. The patient who had miliary tuberculosis received
prolonged (18 months) antituberculous drug therapy (isoniazid, rifampin,
and ethambutol).
Aortobronchial Fistula After TEVAR
Two men (58 and 70 year old) underwent surgical conversion for
secondary aortobronchial fistula after TEVAR. The initial indication for
TEVAR was degenerative descending thoracic aortic aneurysm (n ¼ 1),
and dissecting descending thoracic aortic aneurysm (n ¼ 1). The proximal
landing zone was zone 3 in both patients. The patients had been treated
using the Valiant and the Talent stent graft. These 2 patients had a chronic
type I (distal) and type II endoleak.
Pulmonary segmentectomy was performed in both patients via a left
thoracotomy and coverage of the stent graft was achieved using a pleural
flap in 1 patient and the serratus muscle in the other (Figure 2).
Both patients received broad-spectrum intravenous antibiotics for
6 weeks followed by lifelong oral antibiotic suppression.TABLE 1. Clinical presentation at diagnosis
Patient Gender
Age
(years) Hemoptysis
Fever>38C
or<36C Hyperleukocytosis
R
ra
1 Female 75 Yes Yes Yes
2 Female 84 Yes Yes No
2 Male 89 Yes Yes Yes
4 Male 58 Yes Yes No
5 Male 70 Yes Yes Yes
SIRS, Systemic inflammatory response syndrome (2 or more of the following variables are
respiratory rate>20 breaths/min or arterial carbon dioxide tension (PaCO2)<32 mmHg; abn
Anesthesiologists.
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All patients survived the surgical procedure. Four
patients had an uneventful postoperative course. After a
mean follow-up of 23.2 months, these 4 patients are
asymptomatic. Postprocedure computed tomography (CT)
scans, white cell counts, and C-reactive protein levels
were unremarkable. In the 2 individuals who underwent
complementary follow-up with positron emission tomo-
graphy scans, normalization of the metabolism around the
stent graft was demonstrated (Figure 2).
One patient treated for an aortobronchial fistula
after TEVAR was readmitted 4 months after surgical
conversion for severe mediastinitis with thoracic stent graft
infection. Via a redo left thoracotomy, on femoro-femoral
cardiopulmonary bypass, the stent graft was explanted
and the descending thoracic aneurysm was repaired using
a silver-coated tube graft. The postoperative course was
uneventful and after a follow-up of 6 months, the patient
remains asymptomatic. The postprocedure CT scan at 18
months did not identify any abnormalities.DISCUSSION
Aortobronchial fistula is a rare diagnosis. Conservative
nonsurgical therapy results invariably in a fatal outcome
as a result of massive hemoptysis or chronic mediastinitis.
Causes of aortobronchial fistula formation include
thoracic aortic aneurysms, advanced lung cancer,
pulmonary infections, and open or endovascular repair of
the thoracic aorta. With the increasing use of thoracic
stent grafts, the number of patients treated for aortobron-
chial fistula after TEVAR has increased. The incidence of
aortobronchial fistula after TEVAR is not negligible
(1.7%), and is comparable to that after open repair.3 This
warrants an ad hoc long-term follow-up after TEVAR,
particularly in patients who have undergone emergency or
complicated procedures. The postulated cause of aortobron-
chial fistula after TEVAR includes stent graft coverage of
the bronchial arteries leading to ischemic necrosis of the
bronchial wall, chronic endoleaks leading to erosion into
the adjacent lung, and penetration of the stent graft through
the aortic wall into the lung.4 In our 2 patients who
experienced an aortobronchial fistula after TEVAR, chronicespiratory
te>20/min
Heart rate
>90/min SIRS ASA score Bacteriology results
Yes Yes Yes 4 0
No No No 4 Mycobacterium tuberculosis
Yes Yes Yes 4 0
Yes No No 3 0
Yes Yes Yes 3 0
present: temperature>38C (100.4F) or<36C (96.8F); heart rate>90 beats/min;
ormal white blood cell count [>12,000/mL or<4000/mL]); ASA, American Society of
diovascular Surgery c Volume 148, Number 5 2109
TABLE 2. Demographic data and survey of patients treated by a combined endovascular and surgical approach for an aortobronchial fistula
Patient Gender
Age
(years) Aortic pathology
Stent
graft
Time to
conversion Conversion Outcome
Follow-up
(months)
1 Female 75 Primary aortobronchial
fistula
C-Tag 0 d Left upper lobectomy
Aortic debridement
Pleural flap
Discharged 43
2 Female 84 Primary aortobronchial
fistula
Valiant 7 d Left lower lobectomy
Aortic debridement
Pleural flap
Discharged 23
2 Male 89 Primary aortobronchial
fistula
C-TAG 7 d Left lower segmentectomy
Aortic debridement
Pericardial flap
Discharged 3
4 Male 58 Secondary aortobronchial
fistula after TEVAR
Valiant 28 mo Pulmonary segmentectomy
Aortic debridement
Pleural flap
Discharged 24
5 Male 70 Secondary aortobronchial
fistula after TEVAR
Valiant 13 mo Pulmonary segmentectomy
Aortic debridement
Serratus muscle flap
Stent graft infection
Descending aortic
replacement
14
TEVAR, Thoracic endovascular aneurysm repair.
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Dendoleak was the most likely mechanism for the formation
of aortobronchial fistula (these 2 patients had a chronic type
I and type II endoleak). Characteristics such as the number
of stent grafts used and the length of the aorta covered have
not been found to be significant.3
Open repair involves combined replacement or bypass of
the thoracic aorta with concomitant resection or repair ofFIGURE 1. A patient treated for a primary aortobronchial fistula in a staged f
mobilization. C, The lower left lung fistula was treated by pulmonary segmentect
achieved using a pericardial flap (2). The pericardial defect was addressed with
2110 The Journal of Thoracic and Cardiovascular Surthe lung involved. Despite significant refinement in surgical
techniques, the operative mortality of open aortoesophageal
fistula repair has been reported to be up to 41%.2 Several
alternative strategies have recently been reported in the
literature. Since 1996, 124 patients treated by TEVAR for
an aortobronchial fistula have been reported. The peri-
operative outcomes of the endovascular approach wereashion. A, Intraoperative view. B, The stent graft (1) is exposed after lung
omy. Aortic debridement was performed and coverage of the stent graft was
bovine pericardium (3).
gery c November 2014
FIGURE 2. Positron emission tomography scan of a patient treated for a primary aortobronchial fistula caused by pulmonary tuberculosis. A, 3 months
after discharge: hypermetabolism of the thoracic stent graft, maximum standardized uptake value 10.1. B, 25 months after discharge: no hypermetabolism of
the thoracic stent graft, maximum standardized uptake value 2.4.
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Dfavorable1: low 30-day mortality (6.4%) and no cases
of paraplegia. The incidence of severe complications
(pulmonary, sepsis, myocardial ischemia) was only
11.3%. In this review, aortobronchial fistula recurred in
11.2% of the patients and surgical conversion was required
in 4.3% of the patients. The evidence emerging from
these results prompted us to change our clinical practice.
However, it is uncertain whether TEVAR alone provides
a complete and durable cure for aortobronchial fistula.
TEVAR does nothing to address the issue of the defect in
the respiratory tract, leaving the patients at risk of
aortobronchial fistula recurrence and/or stent graft
infection. We believe that the bronchial defect should be
addressed. Direct contact between the stent graft and the
pulmonary tissue should be avoided to prevent further
erosive damage. The concomitant repair may entail primary
repair or resection and anastomosis of the bronchus and/or
pulmonary resection with coverage of the stent graft using
muscle or pleural flaps. These patients need to be followed
closely to evaluate the opportunity and the appropriate
timing for a secondary surgical procedure. The treatment
strategy and interval to additional surgical procedures are
individualized according to the patient’s physical condition
and severity of sepsis. This aggressive surgical approach
was efficient in 4 of the 5 patients. The patient who
underwent surgical conversion was treated for a secondary
aortobronchial fistula (after TEVAR). We can speculate that
the risk of stent graft infection is probably higher when the
patient has had a long-standing communication between the
stent graft and the lung without broad-spectrum antibiotic
therapy before the surgical approach to isolate the graft.
Another surgical strategy is to consider TEVAR as a bridge
therapy; in young and fit patients, TEVAR is followed by a
delayed, durable, open repair when the patient has regained
relative physiologic stability.5The Journal of Thoracic and CarLong-term antibiotic therapies must be considered.
Postoperative antibiotics were administered in all our
patients for 6 weeks. A conservative policy for antibiotic
treatment might involve at least 4 weeks of periprocedural
intravenous antibiotics followed by case-specific adminis-
tration of oral suppressive antibiotics according to the
clinical and laboratory parameters of infection.
The main limitation of the present study is that it is
retrospective and the sample size is relatively small.
CONCLUSIONS
The perioperative outcomes of the endovascular
approach for aortobronchial fistula have been favorable.
TEVAR does nothing to address the issue of the defect
in the respiratory tract, leaving the patients at risk
of aortobronchial fistula recurrence and/or stent graft
infection. We believe that the bronchial defect should be
actively managed. The concomitant repair may entail
primary repair or resection and anastomosis of the bronchus
and/or pulmonary resection with coverage of the stent graft
using muscle or pleural flaps. Long-term surveillance and
continued investigation are warranted.
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